

Date: May 13, 2022

## Administrative Circular: 2022:19

ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals

# Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

# Part 4 – Biological Products

### COVID-19 Vaccines

## COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

• Doses and Schedule:

A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed. This applies to doses in their primary series, between primary series and first booster dose and between booster doses.

#### Please remove page numbers: 1-6 dated May 5, 2022 Please add new page numbers: 1-6 dated May 13, 2022

## COVID-19 Vaccine SPIKEVAX™ (Moderna)

### • Doses and Schedule:

A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed. This applies to doses in their primary series, between primary series and first booster dose and between booster doses.

Please remove page numbers: 1-5 dated April 26, 2022 Please add new page numbers: 1-5 dated May 13, 2022





## COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

#### Booster Doses:

**BC Centre for Disease Control** 

Provincial Health Services Authority

- A footnote has been added to indicate the minimum interval between the primary series and booster dose.
- A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed.

Please remove page numbers: 1-4 dated April 26, 2022 Please add new page numbers: 1-4 dated May 13, 2022

#### COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

#### • Booster Doses:

Footnote A has been revised to indicate that while a second dose of COVID-19 mRNA vaccine is recommended at least 6 months after the first booster dose, clients requesting a shorter interval should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between booster doses has been observed.

Please remove page numbers: 1-4 dated April 26, 2022 Please add new page numbers: 1-4 dated May 13, 2022

### COVID-19 Vaccine Nuvaxovid™ (Novavax)

#### Booster Doses:

- A footnote has been added to indicate the minimum interval between the primary series and booster dose.
- A footnote has been added to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval, provided the minimum interval between doses has been observed.

Please remove page numbers: 1-3 dated April 26, 2022 Please add new page numbers: 1-3 dated May 13, 2022





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: <u>stephanie.meier@bccdc.ca</u>).

Sincerely,

deitre brans

Monika Naus MD MHSc FRCPC FACPM Medical Director Communicable Diseases & Immunization Service BC Centre for Disease Control

pc:

Provincial Health Officer Dr. Bonnie Henry

Dr. Reka Gustafson Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer Dr. Martin Lavoie BC Ministry of Health, Population & Public Health Division:

Brian Sagar Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong Executive Director, Public Health, Planning and Prevention, Population and Public Health Division



